Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 12, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in celebrating milestone moments for our portfolio companies.
Corporate ESG
Chontec Pharmaceutical Supports Medical Aid Public Welfare Project, Bringing Hope to Late-Stage Lung Cancer Patients
Initiated by the Quzhou Medical Health and Community Development Foundation and fully supported by Qiming Venture Partners portfolio company Chontec Pharmaceutical, the "First Hope, Life Support" medical aid public welfare project is ongoing. The project focuses on EGFR-positive advanced non-small cell lung cancer patients with central nervous system (CNS) metastasis nationwide, using an innovative drug assistance model to help patients overcome the "last mile" of long-term standardized treatment.
Applications are now open for drug assistance for Ze Ruini® (Zorifertinib Hydrochloride Tablets). Previously, the National Medical Products Administration (NMPA) approved Chontec Pharmaceutical's application for the Class 1 innovative drug Zorifertinib Hydrochloride Tablets (trade name: Ze Ruini®). This drug is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations and CNS metastasis. It is the world's first approved next-generation EGFR-TKI specifically targeting lung cancer brain metastasis.
Major Partnerships
01/
UBTECH Becomes the Exclusive Humanoid Robot Partner for the China Pavilion at Expo 2025 Osaka, Kansai, Japan
Recently, Qiming Venture Partners portfolio company UBTECH (09880.HK) announced that its new commercial humanoid robot Walker C will debut at the China Pavilion at Expo 2025 Osaka, Kansai, Japan, bringing cutting-edge interactive technology experiences to global audiences.
Walker C will serve as the China Pavilion's first Embodied Artificial Intelligence "Ambassador Guide," supporting multilingual interaction through its self-developed embodied intelligent interaction large model. It will engage with visitors at the South Square of the China Pavilion, providing intelligent guided tour and reception services and a brand new human-machine interaction experience.
02/
Hesai Technology and Neolix Deepen Strategic Partnership
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ:HSAI) announced a further deepening of its strategic partnership with Neolix to accelerate the large-scale deployment of Neolix's autonomous vehicles in logistics scenarios. This enhanced collaboration not only further solidifies Hesai Technology's leading position as a lidar supplier in the autonomous vehicle sector, but also injects strong momentum into Neolix's expansion in the smart logistics market.
As the core sensor, Hesai Technology's XT lidar extends the autonomous driving perception system's range to 120 meters, significantly reducing the blind spots that traditional architectures create at close range. Combined with precise calibration, it achieves true "zero blind spots." Whether in adverse weather conditions such as nighttime, rain, or haze, or complex road conditions like narrow roads and toll gates, Neolix autonomous vehicles can operate stably and safely.
03/
Guangzhou Huashang College School of Digital Finance and K2 Venture Partner on Industry-Education Integration
Recently, the School of Digital Finance at Guangzhou Huashang College and Qiming Venture Partners portfolio company K2 Venture have joined forces to officially launch a new chapter in industry-education integration.
This partnership integrates K2 Venture's advanced technologies and business scenarios — such as RPA process automation and AI intelligent analytics — into Guangzhou Huashang College's finance curriculum, cultivating students' digital thinking and technological innovation capabilities. Students will not only acquire solid financial expertise but also become proficient in using digital technologies to solve real-world financial problems, becoming digital-intelligent finance talents who meet the demands of the new era.
R&D Progress
01/
Medicilon's YL201 Phase 1 Study Results for Advanced Solid Tumors Published in Nature Medicine
Recently, Phase 1 clinical study results for Qiming Venture Partners portfolio company Medicilon's B7H3-targeted ADC drug YL201 in the treatment of advanced solid tumors were published in the top international journal Nature Medicine.
Led by Professor Li Zhang's team at Sun Yat-sen University Cancer Center, the study covered 54 centers globally and enrolled 312 patients. It found that YL201 demonstrated significant efficacy in refractory tumors including small cell lung cancer, nasopharyngeal carcinoma, pulmonary lymphoepithelioma-like carcinoma, and non-small cell lung cancer, with objective response rate (ORR) and disease control rate (DCR) both exceeding existing standard treatments, and with manageable safety.
This marks the first time globally that B7H3-targeted drug research results in solid tumors have been published in a formal academic journal, and it is the first reported drug for later-line treatment of pulmonary lymphoepithelioma-like carcinoma. Notably, this clinical trial is an early-stage clinical research project for a domestically developed original drug, led by Chinese investigators with global researcher participation. It represents a milestone achievement under the "domestic innovative drug + global concurrent development" model, demonstrating the international influence of Chinese original drugs.
02/
Abogen Biosciences to Present Research on EGFR-Mutation-Targeted mRNA Cancer Vaccine
Recently, Qiming Venture Partners portfolio company Abogen Biosciences announced that it will present research progress on its EGFR-mutation-targeted mRNA cancer vaccine at the 2025 American Association for Cancer Research (AACR) Annual Meeting, covering preclinical research results and preliminary clinical trial data. The vaccine's clinical research is being conducted in collaboration with The First Affiliated Hospital of Guangzhou Medical University.
ABOR2013 (also referred to as "ABO2013") is a novel mRNA therapeutic cancer vaccine built on Abogen Biosciences' leading technology platform, designed to target EGFR mutations commonly found in non-small cell lung cancer (NSCLC) — including exon 19 deletions, L858R, and T790M — covering both high-frequency primary mutations and common resistance mutations that emerge after first-generation TKI treatment. Preclinical studies have shown that ABOR2013 delivers excellent immunogenicity and significant anti-tumor activity.
Product Launches
01/
Roborock Releases Zeo-cycle Washer-Dryer Z1 Plus and Z1 Drum Washing Machine
Recently, Qiming Venture Partners portfolio company Roborock (688169.SH) launched the Zeo-cycle washer-dryer Z1 Plus and the Z1 drum washing machine.
The Z1 Plus has earned top-tier certifications from The Woolmark Company for both washing and drying; its SteamEase™ steam de-wrinkle and refresh system has achieved Grade A certification from the China Household Electrical Appliances Research Institute for wrinkle removal; the Zeo-cycle™ molecular sieve technology protects clothes through low-temperature drying; the RR Mariner™ full-domain precision control algorithm enables intelligent dispensing of laundry detergent and fabric softener; Roborock FineFoam™ ultra-clean mousse wash achieves an industry-leading cleanliness ratio of 1.2; Roborock LintClear™ 2.0 uses 360° rotating spray for self-cleaning of the lint filter; the ultra-slim design allows seamless integration into home environments; the product delivers near 100% elimination of bacteria, viruses, allergens, and dust mites; and if the user doesn't remove clothes within 30 minutes, the machine automatically blows warm air for intelligent garment care.
The Z1 drum washing machine has earned The Woolmark Company's green label certification for washing and pet-care certification from the China Household Electrical Appliances Research Institute; it also features seamless home integration; dedicated programs for special fabrics can handle materials like Gore-Tex, silk, and wool; a 530mm drum diameter and 12kg extra-large capacity give clothes more room to move; it too achieves near 100% elimination of bacteria, viruses, allergens, and dust mites; and a seven-dimensional shock-absorption balance system ensures quieter operation during washing.
02/ Roborock Launches Smart Self-Emptying Vacuum H50 Ultra
Recently, Qiming Venture Partners portfolio company Roborock (688169.SH) launched the smart self-emptying vacuum H50 Ultra.
Roborock has pioneered a five-in-one all-in-one station that integrates dust collection, filtration, charging, antibacterial protection, and storage, giving users 100 days of hands-free dust disposal. The product is equipped with 280AW top-tier suction power for efficient cleaning, and its filter can go 180 days without cleaning. Roborock's innovative triple unique structural design achieves zero hair tangling throughout the entire cleaning process — from the floor brush and mite removal brush's anti-tangle suction, to the dust cup's anti-tangle collection. The product's high-frequency beating structure powerfully shakes out and sucks up dust particles hidden deep in carpets.
03/ Gan & Lee Pharmaceuticals' Insulin Glargine Approved in Pakistan
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed insulin glargine cartridge formulation, for which it serves as the marketing authorization holder (MAH), has been formally approved by the Drug Regulatory Authority of Pakistan.
This marks the second formulation approval for the same core product, following the 2022 entry of Gan & Lee's insulin glargine pre-filled pen into the Pakistani market as a first-to-generic. It represents a further milestone in the company's deepened presence in Pakistan's diabetes treatment sector, making Gan & Lee the only biopharmaceutical company in the country to achieve first-to-generic breakthroughs for both formulations of insulin glargine.
04/ Pulnovo Medical's PADN Catheter Passes MDR Certification, Gaining European Market Access
Recently, the PADN catheter independently developed by Qiming Venture Partners portfolio company Pulnovo Medical successfully passed the European Union Medical Device Regulation (MDR) certification, becoming the first innovative product in the Class III cardiovascular intervention field to gain approval based on complete, authentic Chinese clinical data. Unlike clinical exemption pathways, this certification means the PADN catheter met the EU's highest standards for safety, efficacy, and scientific rigor without conducting local European clinical trials, relying instead on its solid and credible clinical research outcomes.
Alongside successfully passing MDR certification, Pulnovo Medical's self-developed PADN catheter has also formally received CE marking. This certification represents not only international recognition of the PADN catheter's technological advancement and clinical efficacy, but also validation of the maturity and reliability of its end-to-end quality system. Since 2017, Pulnovo Medical has maintained ISO 13485:2016 quality management system certification for multiple consecutive years. Building on years of stable system operation, the company completed its 2024 audit with zero major non-conformities and successfully passed the EU CE-MDR system certification in 2025. From innovative design and safety performance to clinical data and operational management, the PADN catheter has demonstrated strong capabilities across multiple critical dimensions, truly earning market access to Europe under "Made in China" standards and providing a safer, more effective treatment option for pulmonary hypertension patients worldwide.
05/ InferVision's Lung Surgery Planning Product Receives Class III Medical Device Registration from National Medical Products Administration
Recently, the lung surgery planning software independently developed by Qiming Venture Partners portfolio company InferVision formally received Class III medical device registration from the National Medical Products Administration. As the newest addition to InferVision's surgical planning portfolio, this product represents a major technical breakthrough, with approval for "assisting in surgical plan formulation" — making it China's first lung surgery planning product to receive Class III certification under the "surgical planning" category.
"InferVision founder and chairman Chen Kuan stated: 'A surgeon's most precious time should be spent on the surgery itself. The repetitive work of reconstruction, modeling, mapping, and measurement in surgical planning should be handled efficiently and precisely by AI, freeing up more time for doctors to focus on procedural judgment and surgical operations. Surgical planning directly affects the safety and outcome of operations. The approval of InferVision's new generation of surgical products allows AI to truly enter the core of surgical decision-making, helping surgeons develop high-quality surgical plans and safeguarding patients' lives.'"
06/ Tingsn Technology's TINGSN Sonic Eyes 10Pro Receives Approval
Recently, the TINGSN Sonic Eyes 10Pro disposable intracardiac echocardiography diagnostic catheter, independently developed by Qiming Venture Partners portfolio company Tingsn Technology, formally received approval from the National Medical Products Administration. This is the second intracardiac echocardiography diagnostic catheter from Tingsn Technology, following the TINGSN Sonic Eyes 10.
To meet diverse clinical needs, the Sonic Eyes 10Pro features a miniaturized high-resolution probe that enables real-time imaging of cardiac anatomical structures. Its innovative catheter design significantly improves the precision and safety of transseptal puncture and ablation positioning. The fully touch-controlled interface and intelligent feedback system effectively reduce operator fatigue, providing an efficient and reliable visualization solution for cardiac interventional procedures.
Technology
01/ WeRide to Launch Robotaxi Service in Dubai with Four Hesai LiDARs Per Vehicle
WeRide (NASDAQ: WRD), a Qiming Venture Partners portfolio company and the world's first publicly traded Robotaxi operator, recently announced a strategic partnership with Uber Technologies, Inc. and Dubai's Roads and Transport Authority (RTA). The three parties will collaborate to launch autonomous Robotaxi ride-hailing services in Dubai. This milestone not only advances WeRide and Uber's shared mission of globalizing autonomous driving but also reinforces their joint leadership in applying cutting-edge self-driving technology to benefit users worldwide.
Notably, each vehicle in the current fleet is equipped with four LiDARs developed by Hesai Technology (NASDAQ: HSAI), another Qiming Venture Partners portfolio company.
Under the agreement, WeRide will work with Uber and RTA on a pilot Robotaxi operation in Dubai. WeRide's Robotaxis will be fully integrated into the Uber platform, offering users a seamless and user-friendly autonomous ride experience. The three parties will also explore collaboration on data compliance, safety protocols, and regulatory frameworks to support Dubai's transformation toward an autonomous mobility ecosystem.
This Dubai partnership leverages WeRide's global technical expertise in autonomous driving and Uber's leadership in ride-hailing and mobility solutions worldwide, helping establish Dubai as a pioneering smart transportation hub.
02/ Infinigence AI's Dai Guohao Presents Breakthrough Edge-to-Cloud Inference Results at GenAICon 2025
At the 2025 China Generative AI Conference (GenAICon) Large Model Summit, Dai Guohao, associate professor at Shanghai Jiao Tong University and co-founder & chief scientist of Qiming Venture Partners portfolio company Infinigence AI, delivered the opening keynote, unveiling the company's breakthrough inference acceleration technology system for the first time.
His keynote presentation, Efficient Large Model Inference Technology and Applications, systematically explained the cloud-side inference system semi-PD, which achieved up to 5.6x latency reduction for the DeepSeek-V3 model at equivalent request rates — a service-level innovation. He also publicly introduced for the first time the SpecEE inference framework for edge devices, which delivers 2x speedup over the llama.cpp edge framework on AI PCs and received high marks for acceptance at ISCA 2025.
03/ Yungu Technology Debuts at 2025 Shanghai International Hotel & Commercial Space Expo
At the 2025 Shanghai International Hotel & Commercial Space Expo, Qiming Venture Partners portfolio company Yungu Technology showcased its composite multi-modal robot UP, hotel star robot Gege Youth Edition, intelligent robotic arm, Mini AI retail space, and digital human Yuni.
The experience zone demonstrated Yungu Technology's full-suite ecosystem service solutions for clients, including autonomous check-in systems, in-room control systems, AI online stores, self-service coffee, laundry, and trash collection.
From demand to service delivery, the HDOS (Hospitality Digital Operating System) displayed services in real time, allowing visitors to experience the convenience enabled by technology. Through the "management backend sandbox," the company demonstrated how HDOS improves key metrics such as human service efficiency and consumables management.
04/ HyperStrong Ranks First in China's Cumulative Energy Storage System Installations
The China Electricity Council, an authoritative industry body, recently released the 2024 Electrochemical Energy Storage Power Station Industry Statistics Report. As of year-end 2024, Qiming Venture Partners portfolio company HyperStrong ranked first in China for cumulative energy storage system installations.
To date, HyperStrong has participated in over 300 energy storage projects, with more than 25 GWh of commissioned project capacity, establishing itself as a leader in driving the low-carbon energy transition. Projects including the Königssee independent energy storage station in Germany, commercial and industrial projects in Sweden and the Czech Republic, the 1 GWh Sanchahu ultra-large-scale energy storage project in Hami, Xinjiang, the Geely Ronghe Linhai manufacturing base energy storage project, the Zhejiang Longquan semi-solid-state lithium iron phosphate energy storage station, the Anhui Fuyang southern wind-solar-storage base project, and the Huaneng Shandong Xindian power plant energy storage station demonstrate HyperStrong's technical capabilities and delivery capacity both at home and abroad.
05/ Fuwai Hospital Chinese Academy of Medical Sciences National Center for Cardiovascular Diseases Performs Surgery Using Pulnovo Medical's Self-Developed PADN Technology
The Fuwai Hospital Chinese Academy of Medical Sciences National Center for Cardiovascular Diseases recently hosted the "PADN Technology Exchange Seminar," successfully performing Percutaneous Pulmonary Artery Denervation (PADN) on three pulmonary hypertension patients. Qiming Venture Partners portfolio company Pulnovo Medical independently developed PADN technology and continues to advance the high-quality development of pulmonary vascular interventional treatment through technological innovation, joining national experts in witnessing PADN's solid clinical implementation at authoritative medical institutions.
As another successful application of PADN at a top-tier national medical institution, this event not only demonstrated PADN's stable efficacy across different patient types but also provided valuable clinical experience for its broader adoption in pulmonary hypertension treatment.
06/ MicroTech Medical Debuts at 3rd China Advanced Technologies and Treatments for Diabetes & Obesity Conference
As the only Chinese company with a full product ecosystem spanning "monitoring devices + treatment devices + software platforms" in the diabetes field, Qiming Venture Partners portfolio company MicroTech Medical (02235.HK) recently showcased its self-developed hybrid closed-loop artificial pancreas system at the 3rd China Advanced Technologies and Treatments for Diabetes & Obesity Conference (CATTD&O).
The artificial pancreas system consists mainly of a continuous glucose monitor, a closed-loop control algorithm, and a patch insulin pump. Under the control of the closed-loop algorithm, the system maximally simulates healthy physiological insulin secretion, improving patients' time in range. This "smart engine" powered by intelligent algorithms represents more than a decade of MicroTech Medical's deep work in diabetes medical devices — combining technology and clinical research. Once officially launched, it will fill the gap for a China-developed artificial pancreas product on the market.
07/ Zhouzi Future's Pilot-Scale Cell-Cultured Pork Production Technology Passes Scientific and Technological Achievement Evaluation
Recently, the Chinese Institute of Food Science and Technology organized an expert panel in Nanjing to evaluate the achievement "Pilot-Scale Production Technology for Cell-Cultured Pork," jointly completed by Qiming Venture Partners portfolio company Zhouzi Future and Nanjing Agricultural University.
The expert committee identified three breakthroughs in this achievement. First, it established a驯化 method for transitioning seed cells from adherent culture to carrier-free suspension culture, constructing suspension-cultured seed cell lines suitable for industrial-scale production — breaking through the long-standing bottleneck of lacking industrial-grade suspension-cultured cell lines in the cell-cultured pork field. Second, it created a serum-free culture medium development platform combining high-throughput screening with artificial intelligence, developing a low-cost, food-grade serum-free medium that solves the technical challenge of serum-free medium scarcity in cell-cultured pork production. Third, it established for the first time a stepwise scale-up production process, completing carrier-free suspension放大 production of cell-cultured pork in a 500L bioreactor. The overall technology of this project achievement is at an internationally leading level.
08/ Bondent Debuts at IDS Cologne
International Dental Show
Recently, Qiming Venture Partners portfolio company Bondent showcased multiple innovative products and solutions at the IDS International Dental Show in Cologne, Germany, including the Bojue CBCT, Bondent microscope, Bondent dental chair, and EasyRoot M3 endodontic equipment.
In the product experience zone, dental experts personally experienced the high flexibility and smooth handling of the EasyRoot M3 endodontic files, gained in-depth understanding of the Bojue CBCT's precise artifact reduction capabilities, and explored the higher-definition, more refined visual experience under the microscope. Experts also discussed on-site how to optimize clinical workflows through digital technology, sharing applications of AI-enabled intelligent diagnosis and treatment across full scenarios.
09/ Bondent's 7,000th Bojue CBCT Unit Installed in Bangkok, Thailand
Recently, the 7,000th Bojue CBCT unit under Qiming Venture Partners portfolio company Bondent was officially installed in Bangkok, Thailand. This marks another important milestone for Bondent in the global oral imaging field, and represents a solid step forward for Chinese independent brands going global.
From thousands of oral medical institutions across China to over 40 countries and regions worldwide, Bojue CBCT continues to expand its footprint. In the Middle East and Africa, Europe, Latin America, and Southeast Asia, it has become a trusted "China Smart Manufacturing" brand among local dentists. This reflects Bojue CBCT's mission to provide precise diagnosis and treatment for global oral patients — each installation means Bondent brings more advanced technology and better service quality to local oral healthcare.
Corporate Honors
01/ Multiple Qiming Venture Partners Portfolio Companies Selected for 2025 Zhongguancun Forum Annual Conference Major Scientific and Technological Achievements
At the opening ceremony of the 2025 Zhongguancun Forum Annual Conference, ten major scientific and technological achievements were released. The "Beijing AI Innovation Application Achievements," jointly released by Qiming Venture Partners portfolio companies Xiaomi (01810.HK), Zhipu AI, Galaxy Universal, Shengshu Technology, and other institutions, as well as the "Beijing Major Open-Source Achievements" jointly released by Zhipu AI, were selected.
Xiaomi's achievement was "AI-Enabled High-Performance Alloy Material R&D at Xiaomi," which improved R&D efficiency by several orders of magnitude and rapidly identified new die-casting solutions with optimal performance and environmental benefits. Zhipu AI's achievement was "AI Tools Bringing Personalized Learning into Reality" — leveraging the powerful capabilities of its fully self-developed GLM foundation large model, Zhipu AI has built a complete suite of model products matching advanced international standards, including the AI productivity assistant Zhipu Qingyan, the AI video generation product Qingying, and the large model intelligent interaction agent Auto GLM. Galaxy Universal's achievement was "Humanoid Robot Smart Pharmacy Solution" — the smart pharmacy operates 24/7 unmanned through the embodied large model robot Galbot, utilizing end-to-end embodied large models, end-to-end navigation, and other advanced key technologies. This solution addresses traditional pharmacies' challenges of insufficient staffing, limited service hours, and high operating costs, while providing a replicable demonstration model for the intelligent retail industry with broad promotion value in commercial retail, industrial, and logistics sectors. Shengshu Technology's Vidu is China's first fully self-developed, long-duration, high-consistency, high-dynamism video large model, currently available globally. Vidu supports three core functions: text-to-video, image-to-video, and reference-to-video, with leading advantages in inference speed, consistency, dynamism, and semantic understanding.
Zhipu AI jointly released the "Beijing Major Open-Source Achievements" through its open-source foundation model. As China's earliest AI company to open-source large models, Zhipu AI has been committed to advancing AI accessibility. 2025 will be Zhipu AI's open-source year — the company plans to release new large models (including foundation models, reasoning models, multimodal models, Agents, etc.) and open-source them.
02/ Five Founders of Qiming Venture Partners Portfolio Companies Selected for China AI 100 Youth Pioneers List
At the Future AI Pioneers Forum of the 2025 Zhongguancun Forum Annual Conference, DeepTech and MIT Technology Review officially released the China AI 100 Youth Pioneers List. Selected from Qiming Venture Partners portfolio companies were: Bao Fan, co-founder and CTO of Shengshu Technology; Dai Guohao, co-founder and chief scientist of Infinigence AI; He Wang, founder and CTO of Galaxy Universal; Linfeng Zhang, founder and chief scientist of DeepWise; and Xiangyu Zhang, co-founder and chief scientist of StepFun.
The expert review process comprehensively evaluated technological innovation, industrial落地, industry impact, cross-disciplinary exploration, and social responsibility to select youth pioneer representatives working in artificial intelligence across China.
03/ Over 10 Qiming Venture Partners Portfolio Companies Selected for 2024 Annual High-Growth Technology Enterprises and Best CEO Lists
Recently, Diyixinsheng officially released the 2024 Annual High-Growth Technology Enterprises and Best CEO Lists. These lists aim to identify outstanding Chinese technology companies that attract capital market attention while earning recognition from customers and markets — high-tech, high-growth companies with strong teams, good reputations, and cross-cycle resilience — as well as the best CEOs and best young CEOs who possess international vision, industry insight, and leadership capabilities to guide enterprises into a new era.
The 2024 annual lists include two major categories: enterprise lists and CEO lists, with four sub-lists covering comprehensive enterprise rankings, enterprise segment rankings, enterprise vertical industry rankings, and technology CEO rankings, encompassing listed companies, unicorns, future unicorns, and emerging enterprises at different stages.
Qiming Venture Partners portfolio companies Xiaomi (01810.HK) and Meituan (03690.HK) made the High-Growth Listed Companies list, while Zhipu AI, Biren Technology, and StepFun were named to the High-Growth Unicorn Companies list. Galaxy Universal, Infinigence AI, and Yunhe Zhiwang appeared on the High-Growth Future Unicorn Companies list. Zhipu AI, StepFun, and Galaxy Universal were recognized on the High-Growth AI Companies list, Transwarp Technology (688031.SH) on the High-Growth Data Intelligence Companies list, Chaitin on the High-Growth Cybersecurity Companies list, WeRide (NASDAQ:WRD) on the High-Growth Autonomous Driving Companies list, Biren Technology on the High-Growth Chip and Semiconductor Companies list, Meituan, Xiaomi, and Bilibili (NASDAQ:BILI, 09626.HK) on the High-Growth Internet Companies list, and Xiaomi and Roborock (688169.SH) on the High-Growth Consumer Electronics Companies list. Zhipu AI was also named Best Service Provider in Retail Technology.
Xiaomi founder, chairman, and CEO Lei Jun; Meituan founder, executive director, CEO, and chairman Xing Wang; Zhipu AI CEO Peng Zhang; and WeRide founder and CEO Tony Han were honored as Best CEOs in China's Technology Industry. Galaxy Universal founder and CTO He Wang, and DeepWise founder and CEO Weijie Sun were named Best Young CEOs in China's Technology Industry.
04/ Thorough Future Named to Top 10 AI List at 8th Zhongguancun International Frontier Technology Competition
During the 2025 Zhongguancun Forum Annual Conference, the final results of the 8th Zhongguancun International Frontier Technology Competition were officially announced, with Qiming Venture Partners portfolio company Thorough Future selected for the Top 10 AI list. This honor not only highlights Thorough Future's leading capabilities in pathology AI, but also demonstrates the profound value of artificial intelligence in healthcare.
As a leading enterprise in pathology AI, Thorough Future has launched its discriminative pathology AI diagnostic product Thorough Insights. Built on the Thorough Brain pathology foundation model, the product focuses on precise diagnosis of high-incidence tumor organs, efficiently identifying malignant tumors and performing subtyping while also providing intelligent diagnostic support for benign lesions. The system precisely marks cancerous regions through heatmaps and automatically generates structured pathology diagnostic reports.
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 11, 2025
Qiming Stars | WeRide Partners with Uber and Dubai's RTA to Launch Robotaxi Service in Dubai
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.